Status:
ENROLLING_BY_INVITATION
Magnetoencephalography in Psychosis Program
Lead Sponsor:
Douglas Mental Health University Institute
Conditions:
Schizophrenia Disorders
Psychosis
Eligibility:
All Genders
18-50 years
Brief Summary
This research involves the examination of speech, thinking patterns and symptoms and recordings from brain's activity in patients with schizophrenia. The reserchers are investigating if the electrical...
Detailed Description
Schizophrenia is a common and severe mental illness affecting millions of people worldwide. With a lifetime prevalence of about 1%, it is estimated to generate annual costs of $10 billion in Canada al...
Eligibility Criteria
Inclusion
- Patients:
- Clinical diagnosis of schizophrenia as per DSM-5 criteria.
- Aged between 18 and 50 years.
- In a stable phase of the illness (no change in Global Functioning \> 10 units within 1 month before the MEG scan assessed using the Global Assessment of Functioning Scale).
Exclusion
- Inability to speak English or French.
- History of head trauma, major neurological disorders (e.g., epilepsy), somatic disorders with neurological complaints (e.g., multiple sclerosis), or intellectual disabilities.
- Diagnosis of substance use disorder (current or within the last year) as per DSM-5.
- Unsuitable for MRI due to safety concerns (e.g., metal in the body, pregnancy, tinnitus).
- Healthy Controls
- Inclusion Criteria:
- Healthy volunteers aged between 18 and 50 years.
- Matched to patients for age (within 2 years), sex, and parental occupational status (rated by NS-SEC).
Key Trial Info
Start Date :
May 8 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06978881
Start Date
May 8 2024
End Date
November 1 2026
Last Update
May 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Douglas Mental Health University Institute
Montreal, Quebec, Canada, H4H 1R3